Luke Halpern, Assistant Editor

As a rare and serious pediatric disorder, Stargardt disease can cause vision complications in patients.

No acute serious bacterial infections were observed in a trial of patients with the debilitating immune disorder, a strong mark of safety and tolerability.

Through an assignment to create a TikTok infomercial, students master new concepts and have positive educational experiences via social media.

Severity of a COVID-19 illness could be determined by examining autoantibodies in the nasal cavity, allowing more personalized treatment protocols.

Inflammation associated with asthma in children could perturb neurodevelopment.

GNSC-001 is a first-in-class gene therapy designed to offer long-term relief of musculoskeletal diseases such as osteoarthritis.

When compared to established diagnostic assays such as the basophil activation test, the Hoxb8 mast cell activation test demonstrates similar precision.

The tablets become the first and only nilotinib with no mealtime restrictions indicated for this population.

IVIG was found to cease development of new lesions and heal previously documented erosions without adverse events to the patient or fetus.

The strongest association is found between asthma and the risk of attention deficit/hyperactivity disorder, though these links do not equate to causality.

Karyne Jones highlights the importance of pneumococcal vaccination for those 50 years and older, especially in communities of color.

High COVID-19 hospital caseload strain led to increases in inpatient adverse events among patients both with and without SARS-CoV-2 infection.

In the trial, lumateperone had a significantly longer time to relapse in patients treated compared to placebo.

The regulatory approval corresponds with positive safety and efficacy data from the FELIX trial.

Glucagon-like peptide-1 agonists have increasingly showed potential for treating liver fibrosis in patients, which disproportionately affects those who are overweight or have obesity.

Reasons for supporting the lowering of the age-based pneumococcal vaccine recommendation included the likelihood it would increase vaccination rates in multiple age groups and demographics.

Though both vaccines remain effective at preventing severe illness, Moderna’s mRNA-1273.222 vaccine was found to be significantly more effective among adults with underlying medical conditions.

The drug is being investigated for its potential to reduce fibrosis associated with muscular dystrophy that can cause scarring of the heart tissue.

Tripp Logan, PharmD, reflects on being named Independent Pharmacist of the Year from the National Community Pharmacists Association.

Children with certain atopic conditions, including asthma and common food allergies, were observed to have a higher risk of developing the chronic disorder.

Efforts include a mandatory intravenous immunoglobulin ordering form, blood bank gatekeeping, and a stewardship committee to ensure optimized use.

Brian Anderson, PharmD, RPh provides important considerations for pharmacists regarding patient use of benzodiazepines.

Known to be a leading cause of mortality worldwide, cigarette smoke exposure can make the respiratory tract more susceptible to pneumococcal infection.

Recently announced trial results demonstrate the efficacy of the biologic in multiple disease indications.

In children aged 12, 18, and 24 months, there was no association between maternal COVID-19 exposure and abnormal scores on a neurodevelopment screening.

Intravenous immunoglobulin prescriptions deemed non-compliant according to French national guidelines were more common in younger patients.

Patients with hereditary angioedema who received sebetralstat earlier had faster complete resolution of their attacks.

The risk of developing lymphoma remained nearly the same between patients with Crohn disease and ulcerative colitis.

Results indicate that sublingual epinephrine can resolve symptoms, including swelling of the face and throat, associated with oral allergy syndrome in minutes.

Though auto-injectors are still considered an appropriate first-line treatment for anaphylaxis, limited evidence exists surrounding their effectiveness in preventing fatal anaphylaxis.